Venus Remedies has accord exclusive marketing rights for its novel antibiotic product - Potentox - to South Africa's pharmaceutical giant Adcock in a deal. Adcock will have exclusive marketing rights of the products in South Africa over the period of 15 year. The product will remain under patent protection till 2025 in African territory and is expected to be launched by mid of 2015 after getting due regulatory approvals.
Potentox is a research based antibiotic product of the company protected by patent in USA and in number of other countries across the Globe including India, Canada, Australia, New Zealand, South Korea, South Africa and Ukraine. Potentox is an antibiotic adjuvant entity (AAE); a new drug product effective in case of Hospital Acquired Pneumoniae and Febrile Neutropenia infections, including Penicillin and Multidrug resistant case proved through clinical studies on more than 500 patients, which has also indicated approximately 20-30% reduction in the cost of therapy as compared to conventional therapies being used.
Adcock Ingram having a heritage of more than 120 years is a leading South African manufacturer, marketer and distributor of healthcare products with a market capitalization of $2 billion. The Group enjoys a 10% share of the private pharmaceutical market in South Africa with a strong presence in over-the-counter brands. The company is South Africa’s largest supplier of hospital and critical care products. Its footprint extends to other territories in sub-Saharan Africa and India.
Venus Remedies is a pharmaceutical manufacturing company. The company provides formulations in area of antibiotics and oncological therapeutics. The company has two manufacturing facilities located in India and Germany. It manufactures Oncological and Cefelosporine Injectable products.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: